© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
April 21, 2022
The analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.
April 20, 2022
Analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.
April 19, 2022
Session highlights novel agents that have recently entered, or will imminently enter, into phase 1 clinical trials.
April 14, 2022
The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.
Results are from an exploratory analysis of 34 patients who received at least 1 dose after disease progression or suboptimal response with ruxolitinib monotherapy
Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).
April 13, 2022
Sotorasib demonstrates clinical benefit and prolonged tumor response seen, with a 40.7% objective response rate.
April 11, 2022
Peptide-targeted radionuclide therapy FAP-2286 (Clovis Oncology) showed potent affinity for human fibroblast activation protein by biochemical and cell-based assays.
Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.